Cash, cash equivalents and investments as of September 30, 2025, were $66.5 million. The Company believes its cash, cash equivalents and investments are sufficient to fund planned operations into Q1 of 2027.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO:
- ALXO Earnings this Week: How Will it Perform?
- Alx Oncology’s ALX2004: A Promising Phase 1 Study Targeting EGFR in Solid Tumors
- ALX Oncology’s ASPEN-09 Study: A Promising Update for Cancer Treatment
- ALX presents preclinical data, Phase 1 trial-in-progress for ALX2004
- ALX Oncology Announces Management Changes Amidst Nasdaq Compliance